Teva Pharmaceutical Industries Ltd

Teva’s EMA approval of its olanzapine long‑acting injectable expands its portfolio into high‑margin psychiatry, boosting revenue prospects and positioning the company for global growth.

Teva’s Q1 2026 earnings beat expectations, boosting brand sales, analyst upgrades, and ESG momentum—signaling a strong upside for investors and a rising valuation.

Teva’s FDA approval of a long‑acting schizophrenia drug, coupled with a landmark patent win, signals strong growth prospects for the Tel Aviv‑listed pharma giant.

Teva Pharmaceutical: Institutional shifts, BofA’s raised price target, and a P/E of 25.14 make it a discounted strong‑buy for value‑seeking investors.

Teva’s bullish move into bispecific antibodies fuels a dual‑stream growth story, blending a robust generic legacy with high‑margin specialty‑pharma prospects for investors.

Teva’s FDA‑approved Prolia biosimilar sparks a rally amid volatility, showing promise yet highlighting past losses and the need for sustained growth.

Teva Pharmaceutical Industries Ltd’s Q4 earnings beat, growth‑oriented pipeline, and disciplined outlook hint at upside potential for investors, despite modest FY‑26 guidance.

Teva Pharmaceutical’s stock surge, legal challenges, and investor gains revealed – explore how lawsuits over Victoza and Harel’s stake impact its future.

Teva secures EU approvals for two denosumab biosimilars, PONLIMSI and DEGEVMA, expanding its bone‑health portfolio and boosting market share prospects.